Generic Name

Nitisinone

Brand Names
Harliku, NITYR, Orfadin
FDA approval date: June 01, 2016
Classification: 4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor
Form: Tablet, Suspension, Capsule

What is Harliku (Nitisinone)?

HARLIKU TM is indicated for the reduction of urine homogentisic acid in adult patients with alkaptonuria . HARLIKU is a hydroxyphenyl-pyruvate dioxygenase inhibitor indicated for the reduction of urine homogentisic acid in adult patients with alkaptonuria .

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Rational Design of Small-Molecule Stabilizers of Human Fumarylacetoacetate Hydrolase for the Treatment of Tyrosinemia Type I.
Rational Design of Small-Molecule Stabilizers of Human Fumarylacetoacetate Hydrolase for the Treatment of Tyrosinemia Type I.
Journal: Journal of medicinal chemistry
Published: May 12, 2026
Morphological characterization of a novel model of steatohepatitis in the FAH-/- pig.
Morphological characterization of a novel model of steatohepatitis in the FAH-/- pig.
Journal: Veterinary pathology
Published: January 17, 2026
Effect of Nitisinone on Aortic Stenosis Disease Progression in Patients With Alkaptonuria: An Analysis of the Suitability of Nitisinone in Alkaptonuria (SONIA) 2 Study.
Effect of Nitisinone on Aortic Stenosis Disease Progression in Patients With Alkaptonuria: An Analysis of the Suitability of Nitisinone in Alkaptonuria (SONIA) 2 Study.
Journal: Cureus
Published: December 26, 2025
View All Latest Advances

Brand Information